Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Revenue (2016 - 2025)

Historic Revenue for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $20.6 million.

  • Harvard Bioscience's Revenue fell 627.67% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.4 million, marking a year-over-year decrease of 1060.14%. This contributed to the annual value of $94.1 million for FY2024, which is 1613.81% down from last year.
  • Per Harvard Bioscience's latest filing, its Revenue stood at $20.6 million for Q3 2025, which was down 627.67% from $20.4 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Revenue high stood at $33.1 million for Q4 2021, and its period low was $20.4 million during Q2 2025.
  • Its 5-year average for Revenue is $26.4 million, with a median of $27.0 million in 2021.
  • In the last 5 years, Harvard Bioscience's Revenue skyrocketed by 2526.6% in 2021 and then crashed by 1968.77% in 2024.
  • Harvard Bioscience's Revenue (Quarter) stood at $33.1 million in 2021, then fell by 14.0% to $28.4 million in 2022, then decreased by 0.96% to $28.2 million in 2023, then dropped by 12.78% to $24.6 million in 2024, then fell by 16.15% to $20.6 million in 2025.
  • Its Revenue stands at $20.6 million for Q3 2025, versus $20.4 million for Q2 2025 and $21.8 million for Q1 2025.